Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
Crinetics Pharmaceuticals has submitted a Marketing Authorization Application to Brazil's ANVISA for Palsonify (paltusotine), the first once-daily oral therapy approved in the US for acromegaly. The submission follows positive Phase 3 trial results demonstrating efficacy and tolerability and complements recent regulatory progress in Europe. This ma…